

Gonorrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/G95A849F91D8EN.html>

Date: March 2022

Pages: 71

Price: US\$ 2,000.00 (Single User License)

ID: G95A849F91D8EN

Abstracts

Gonorrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape.

Gonorrhea is a sexually transmitted disease (STD) caused by *Neisseria gonorrhoeae* bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix and endometrium, lining of the eyelid, the throat and fallopian tubes. Symptoms include painful urination, pus-like discharge from penis, increased vaginal discharge, abdominal pain and pelvic pain. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gonorrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases.

The Gonorrhoea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhoea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 3, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Gonorrhoea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhoea (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Gonorrhoea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gonorrhoea (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gonorrhoea (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gonorrhoea (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gonorrhoea (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gonorrhoea (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Gonorrhoea - Overview
- Gonorrhoea - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gonorrhoea - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gonorrhoea - Companies Involved in Therapeutics Development
- Biolitycs Pharma
- Boulos and Cooper Pharmaceuticals Pty Ltd
- Debiopharm International SA
- Entasis Therapeutics Holdings Inc
- GlaxoSmithKline Plc
- Hsiri Therapeutics LLC
- Melinta Therapeutics Inc
- Merck & Co Inc
- Microbiotix Inc
- Nabriva Therapeutics Plc
- Pharmiva AB
- Redx Pharma Plc
- TherapyX Inc
- Yaso Therapeutics Inc
- Gonorrhoea - Drug Profiles
- BCP-1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Biologic for Gonorrhoea - Drug Profile
- Product Description
- Mechanism Of Action

Debio-1453 - Drug Profile

Product Description

Mechanism Of Action

History of Events

edodekin alfa SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

Fusion Protein for Gonorrhea - Drug Profile

Product Description

Mechanism Of Action

gepotidacin mesylate - Drug Profile

Product Description

Mechanism Of Action

History of Events

GneXa10 - Drug Profile

Product Description

Mechanism Of Action

History of Events

gonorrhea vaccine - Drug Profile

Product Description

Mechanism Of Action

gonorrhea vaccine - Drug Profile

Product Description

Mechanism Of Action

gonorrhea vaccine - Drug Profile

Product Description

Mechanism Of Action

KKL-35 - Drug Profile

Product Description

Mechanism Of Action

History of Events

lefamulin acetate - Drug Profile

Product Description

Mechanism Of Action

History of Events

MBX-4132 - Drug Profile

Product Description

Mechanism Of Action

History of Events

methyldopa - Drug Profile

Product Description

Mechanism Of Action

NGoXIM - Drug Profile

Product Description

Mechanism Of Action

History of Events

P-002 - Drug Profile

Product Description

Mechanism Of Action

PEG-2S - Drug Profile

Product Description

Mechanism Of Action

PPCM - Drug Profile

Product Description

Mechanism Of Action

History of Events

RXP-2382 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit DNA Gyrase and Topoisomerase IV for Gonorrhea - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit PBP2 for Gonorrhea - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Tubulin for Gonorrhea and Oncology - Drug Profile

Product Description

Mechanism Of Action

solithromycin - Drug Profile

Product Description

Mechanism Of Action

History of Events

zolidodacin - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gonorrhea - Dormant Projects

Gonorrhea - Discontinued Products

Gonorrhea - Product Development Milestones

Featured News & Press Releases

Mar 19, 2021: PENN STATE: New antibiotic clears multi-drug resistant gonorrhea in mice in single dose

Feb 12, 2021: GARDP welcomes additional funding from UK to develop new treatment for gonorrhoea

Nov 08, 2019: Debiopharm progresses in their stand against drug-resistant N.

Gonorrhoeae with extended CARB-X funding of their Debio 1453 Antibiotic Program

Oct 28, 2019: ?184 million loan funding for urgent hospital upgrades

Sep 30, 2019: GARDP and Entasis Therapeutics initiate global phase 3 trial of Zolidodacin, a first-in-class oral antibiotic for the treatment of Gonorrhea

Jun 27, 2019: Entasis Therapeutics presents on zolidodacin at ASM Microbe 2019

Jun 10, 2019: Entasis Therapeutics announces presentation on zolidodacin at ASM Microbe 2019

May 14, 2019: Institute for Glycomics shares in multi-million dollar grant for ground-breaking gonorrhoea research

Mar 13, 2019: Yaso Therapeutics awarded \$2 million SBIR grant from the National Institutes of Health to complete preclinical studies of a new female contraceptive that prevents disease transmission

Nov 08, 2018: Data from NIH-funded trial offers hope for gonorrhoea treatment

Nov 07, 2018: Entasis Therapeutics announces zolidodacin phase 2 results published in the new England journal of medicine

Jul 25, 2017: Debiopharm International Awarded \$2.6 Million Grant from CARB-X to Support Development of Debio 1453 to Fight Drug Resistant Gonorrhea

Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

Oct 28, 2016: Entasis Therapeutics to Present Data on ETX0914 at IDWeek 2016

Sep 21, 2016: Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment

of Gonorrhea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Gonorrhea, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Gonorrhea - Pipeline by Biolytics Pharma, 2022
Gonorrhea - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, 2022
Gonorrhea - Pipeline by Debiopharm International SA, 2022
Gonorrhea - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Gonorrhea - Pipeline by GlaxoSmithKline Plc, 2022
Gonorrhea - Pipeline by Hsiri Therapeutics LLC, 2022
Gonorrhea - Pipeline by Melinta Therapeutics Inc, 2022
Gonorrhea - Pipeline by Merck & Co Inc, 2022
Gonorrhea - Pipeline by Microbiotix Inc, 2022
Gonorrhea - Pipeline by Nabriva Therapeutics Plc, 2022
Gonorrhea - Pipeline by Pharmiva AB, 2022
Gonorrhea - Pipeline by Redx Pharma Plc, 2022
Gonorrhea - Pipeline by TherapyX Inc, 2022
Gonorrhea - Pipeline by Yaso Therapeutics Inc, 2022
Gonorrhea - Dormant Projects, 2022
Gonorrhea - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gonorrhea, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Gonorrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G95A849F91D8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G95A849F91D8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

